What is Bio-Techne Corp's P/E ratio?

Bio-Techne Corp (TECH) has a price-to-earnings (P/E) ratio of 104.10.

What is Bio-Techne Corp's fair value?

Based on GoodMoat's DCF model, Bio-Techne Corp (TECH) has a fair value estimate of $24.69.

Does Bio-Techne Corp pay a dividend?

Yes, Bio-Techne Corp (TECH) pays a dividend with a yield of 0.60% ($0.32 per share).

What is Bio-Techne Corp's market cap?

Bio-Techne Corp (TECH) has a market capitalization of $8.44B.

TECH

Compare Earnings: May 31, 2026

Bio-Techne Corp

Exchange: NASDAQSector: HealthcareIndustry: Biotechnology

Contact: David Clair, Senior Director, Corporate Development [email protected] 612-656-4416 SOURCE Bio-Techne Corporation Related Links https://www.bio-techne.com/

Did you know?

Pays a 0.60% dividend yield.

Current Price

$54.19

+3.80%

GoodMoat Value

$24.69

54.4% overvalued

Profile

Valuation (TTM)

Market Cap$8.44B

P/E104.10

EV$8.28B

P/B4.40

Shares Out155.81M

P/Sales6.95

Revenue$1.22B

EV/EBITDA38.07

Bio-Techne Corp (TECH) Stock Analysis

GoodMoat Analysis

Based on data as of March 26, 2026

Bio-Techne appears to be a high-quality business with a potentially durable competitive moat, but it is currently trading at a valuation that is deeply unfavourable from a value investing perspective. The stock price is more than double the GoodMoat Target, indicating a severe lack of margin of safety. This combination makes it an unlikely candidate for a value investor's portfolio without a significant price correction.

Read full analysis

Bio-Techne Corp operates in the biotechnology sector, providing tools, instruments, and reagents for life science research and clinical diagnostics. Applying the GoodMoat Investment Framework, the business likely possesses a durable moat, scoring well on criteria like proprietary data, niche dominance in specific research areas, and potentially high switching costs for its mission-critical reagents and assays. This suggests a Moat Score likely exceeding the 5+ threshold required to proceed. The company also exhibits signs of quality, such as a reasonable debt-to-equity ratio of 0.23 and a positive free cash flow yield of 3.1%. However, the valuation assessment reveals a critical problem. The stock trades at a P/E of 101.2, which is extremely high for a company with negative YoY revenue growth (-0.4%) and a modest profit margin of 6.7%. Most importantly, the current price of $52.37 is more than 110% above the GoodMoat Target of $24.66, indicating a deeply unfavourable margin of safety. Following the Decision Framework, while the business may pass the Moat & Quality Gate, it fails the Valuation & Risk Gate decisively. The extreme valuation, coupled with the negative revenue growth, presents multiple high-confidence red flags. For a value investor, this represents a classic case of a good business at a very bad price, making further investigation at this level unfavourable. Analysis based on data as of 2024-05-15.

TECH Price Chart

Market Cap$8.44B

Current Price$54.19

P/E Ratio104.10

Forward P/E—

PEG Ratio11.45

EPS$0.46

Book Value$12.31

P/B Ratio4.40

FCF vs CAPEX

FCFCAPEX

Forward estimates use 8.6% FCF growth (CAGR)

Cash vs Debt

Net Debt: 282M

Revenue

714M

FY19

739M

FY20

931M

FY21

1.1B

FY22

1.1B

FY23

1.2B

FY24

1.2B

FY25

Net Income

96M

FY19

229M

FY20

140M

FY21

272M

FY22

285M

FY23

168M

FY24

73M

FY25

TECH 52-Week Range

$46.46

$71.28

50-Day MA: $55.24200-Day MA: $58.00

Did you know?

Price sits at 31% of its 52-week range.

Financial Performance

In FY25, Bio-Techne Corp reported revenue of $1.22B, up 5.2% year-over-year. Net income was $73.40M. EPS was $0.46.

TECH Revenue History
Year	Revenue
FY21	$931.03M
FY22	$1.11B
FY23	$1.14B
FY24	$1.16B
FY25	$1.22B

View Financials →

Bio-Techne Corp (TECH) Financial Summary

Bio-Techne Corp (TECH) is a Healthcare company in the Biotechnology industry, listed on NASDAQ. The stock currently trades at $54.19 with a market capitalization of $8.44B.

Key valuation metrics include a P/E ratio of 104.10, price-to-book ratio of 4.40, and EPS of $0.46. The company reports a profit margin of 6.7% and return on equity of 4.2%.

TECH Key Financial Metrics

Metric	Value
Market Cap	$8.44B
P/E Ratio	104.10
EPS	$0.46
P/B Ratio	4.40
P/S Ratio	6.95
EV/EBITDA	38.07
Dividend Yield	0.60%
Profit Margin	6.7%
Return on Equity	4.2%
Debt/Equity	0.23

TECH Revenue & Earnings History

Year	Revenue	Net Income
FY19	$714.01M	$96.07M
FY20	$738.69M	$229.30M
FY21	$931.03M	$140.41M
FY22	$1.11B	$272.05M
FY23	$1.14B	$285.26M
FY24	$1.16B	$168.10M
FY25	$1.22B	$73.40M

Bio-Techne Corp (TECH) Valuation

Based on GoodMoat's DCF model, Bio-Techne Corp has a fair value estimate of $24.69. At the current price of $54.19, the stock appears 119.4% overvalued relative to our intrinsic value estimate.

TECH Quality Indicators

Bio-Techne Corp maintains a profit margin of 6.7% and an operating margin of 8.4%. Return on equity stands at 4.2%. The current ratio is 3.46. Debt-to-equity ratio is 0.23.

About Bio-Techne Corp